



Medgate Licence Agreement – Clarification Announcement

Brisbane, Australia, 11 July 2022 – ResApp Health Limited (ASX:RAP), refers to its announcement released on 7 July 2022 announcing a 12 month extension to its commercial licence agreement with Medgate AG (“Medgate”) to use ResApp’s smartphone-based acute respiratory diagnostic test, ResAppDx, on Medgate’s telehealth platform (“Medgate Licence Agreement”).

ResApp confirms that the key terms of the Medgate Licence Agreement remain unchanged (refer ASX announcement 4 August 2021). At this point in time, ResApp does not anticipate that the Medgate Licence Agreement will have a material impact on its operating results.

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.